Interview: Evaluating an Innovative Analytical ID Testing Strategy for Oligonucleotides

Significance of the Topic

Oligonucleotide-based therapeutics represent a rapidly growing class of biopharmaceuticals requiring precise identification in quality control to guarantee patient safety and meet regulatory standards. Conventional ID methods such as MS/MS sequencing or NMR deliver high accuracy but involve complex workflows, specialized personnel, and significant costs. A UV-Vis melting temperature (Tm) approach offers a streamlined, cost-effective alternative compatible with cGMP environments.

Objectives and Study Overview

This case study describes how Vetter and Agilent collaborated to develop and evaluate a UV-Vis Tm-based ID testing strategy for oligonucleotides. Key objectives included:

• Evaluating Cary 3500 instrument performance and robustness under varied settings
• Assessing specificity and sensitivity of Tm measurements for single- and double-stranded oligonucleotides
• Establishing a scalable, compliant workflow for QC laboratories

Methodology

Experimental procedures were conducted on the Agilent Cary 3500 UV-Vis spectrophotometer. Principal features of the method:

• Integrated Peltier element and in-cuvette temperature probes for precise thermal control
• Multizone configuration enabling parallel measurement of samples and references
• Temperature ramp rate set to 10 °C per minute, yielding approximately 10-minute runs
• Application of smoothing and derivative algorithms via specialized software

Instrumentation Used

• Agilent Cary 3500 UV-Vis system with multizone Peltier temperature control
• In-cuvette temperature probes for accurate real-time monitoring
• Agilent software compliant with 21 CFR Part 11 for regulated laboratories

Main Results and Discussion

Tm analysis on the Cary 3500 provided robust, reproducible data:

• Single-base exchanges, insertions, or deletions produced clear Tm shifts, confirming high specificity
• Analytical performance remained consistent across parameter variations, demonstrating robustness
• The method distinguished closely related oligonucleotide sequences, meeting stringent QC requirements

These findings support a Tm-based ID workflow as a practical, less complex alternative to traditional sequencing approaches.

Benefits and Practical Applications

• Rapid measurement times and straightforward operation facilitate high-throughput QC
• Lower cost of ownership and minimal additional training for existing staff
• Seamless integration into established UV-Vis instrument pools
• Full compliance with cGMP and data integrity standards

Future Trends and Potential Applications

Ongoing efforts aim to develop a validated platform procedure for rapid method transfer to new products. Planned advancements include:

• Software upgrades to enhance data precision and automate analysis
• System-level qualification of analytical functions to streamline validations
• Extension of Tm-based protocols to a broader array of oligonucleotide therapeutics

Conclusion

The UV-Vis Tm-based identification strategy delivers a scientifically robust, cost-efficient, and regulatory-compliant solution for oligonucleotide QC testing. Its ease of use, specificity, and compatibility with cGMP environments position it as a promising standard in pharmaceutical laboratories.

References

• Capaldi D et al Strategies for Identity Testing of Therapeutic Oligonucleotide Drug Substances and Drug Products Nucleic Acid Therapeutics 2020 30(5) 249–264 doi 10.1089/nat.2020.0878
• Schuler S et al Challenging Oligonucleotide ID Testing 8th Annual Oligo Networking Event 23–25 Mar 2021
• Schuler S et al Emerging Therapeutic Oligonucleotides – ID Testing PDA UPS Conference 05–06 Oct 2021
• Heussner AH Emerging Therapeutic Oligonucleotides – Analytical Challenges Accepted PDA UPS Conference 05–06 Oct 2021
• Heussner AH et al Investigating Tm Method Specificity Using Oligonucleotide Sequence Variants Journal of Pharmaceutical Science and Technology 2021 submitted